1. Signaling Pathways
  2. Immunology/Inflammation
  3. TROP2

TROP2 (肿瘤相关的钙信号转导蛋白)

EGP-1; M1S1; GA733-1

TROP2 是一种跨膜糖蛋白,属于 GA733 家族。Trop2 有几种配体,包括 claudin-1、claudin-7 和细胞周期蛋白 D1。Trop2 活性需要受调节的膜内蛋白水解 (RIP)。RIP 通过 TNF-α 转化酶 (TACE) 切割 Trop2,然后在跨膜结构域内进行 γ-分泌酶切割。TROP2 可以激活 ERK1/3-MAPK 通路。TROP2 向细胞发出信号,使其自我更新、增殖、侵袭和存活。Trop2 具有类似干细胞的特性。TROP2 在多种人类癌症中过度表达,包括乳腺癌、宫颈癌、结直肠癌、食道癌(某些类型)、肺癌(某些类型)、非霍奇金淋巴瘤、慢性淋巴细胞淋巴瘤 (CLL)、Rajburkitt 淋巴瘤、口腔鳞状细胞癌、卵巢癌、胰腺癌、前列腺癌、胃癌、甲状腺癌、膀胱癌和子宫癌。

TROP2 is a transmembrane glycoprotein that belongs to the GA733 family. Trop2 has several ligands, including claudin-1, claudin-7, and cyclin D1. Trop2 activity requires regulated intramembrane proteolysis (RIP). RIP cleaves Trop2 by TNF-α converting enzyme (TACE), followed by γ-secretase cleavage within the transmembrane domain. TROP2 can activate the ERK1/3-MAPK pathway. TROP2 signals cells to self-renewal, proliferation, invasion, and survival. Trop2 has stem cell-like properties. TROP2 is overexpressed in a variety of human cancers, including breast, cervical, colorectal, esophageal (some types), lung (some types), non-Hodgkin lymphoma, chronic lymphocytic lymphoma (CLL), Rajburkitt's lymphoma, oral squamous cell carcinoma, ovarian, pancreatic, prostate, gastric, thyroid, bladder, and uterine cancers.

TROP2 相关产品 (6):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132254
    Sacituzumab govitecan Inhibitor 99.13%
    Sacituzumab govitecan (IMMU-132) 是一种抗体-活性分子偶联物 (ADC),靶向 Trop-2 传递 SN-38。Sacituzumab govitecan 具有抗癌活性。
    Sacituzumab govitecan
  • HY-P99045
    Sacituzumab

    戈沙妥珠单抗

    Inhibitor 99.77%
    Sacituzumab 是一种人源化靶向滋养细胞表面抗原 2 (TROP2)IgG1 单克隆抗体。Sacituzumab 单独使用缺乏抗肿瘤作用,在肿瘤转移过程中并不抑制 TROP-2 的功能,能与 TROP-2 蛋白的线性表位结合。Sacituzumab 可用于抗体-药物偶联物 (ADC) 药物的合成。靶向 TROP-2 的 sacituzumab (sacituzumab govitecan) (HY -132254) 抗体-药物偶联物已被批准用于三阴性乳腺癌领域 。
    Sacituzumab
  • HY-141598
    Datopotamab deruxtecan Inhibitor 99.54%
    Datopotamab deruxtecan (DS-1062; Dato-DXd) 是一种滋养层细胞表面抗原 2 (TROP2) 导向的抗体活性分子偶联物 (ADC)。Datopotamab deruxtecan 具有强大的抗肿瘤活性。
    Datopotamab deruxtecan
  • HY-P99843
    Datopotamab

    德达博妥单抗

    Inhibitor 99.00%
    Datopotamab (CDP7657) 是一种人源的抗滋养层细胞表面抗原 2 (TROP2) 抗体。Datopotamab 可以与 DNA 拓扑异构酶 I 抑制剂 Deruxtecan (HY-13631E) 生成抗体-药物偶联物 (ADC) Datopotamab deruxtecan (HY-141598)。Datopotamab 可用于三阴性乳腺癌和非小细胞肺癌的研究。
    Datopotamab
  • HY-132254A
    Sacituzumab govitecan (solution) Inhibitor
    Sacituzumab govitecan (IMMU-132) 是一种抗体-活性分子偶联物 (ADC),靶向 Trop-2 传递 SN-38。Sacituzumab govitecan 具有抗癌活性。
    Sacituzumab govitecan (solution)
  • HY-164789
    Sacituzumab tirumotecan Inhibitor 99.63%
    Sacituzumab tirumotecan (SKB264/MK-2870) 是一种 TROP2 ADC。Sacituzumab tirumotecan 可用于三阴性乳腺癌 (TNBC) 的研究。
    Sacituzumab tirumotecan